Portfolio
Project 2: Investigating NEGR1 for depression
Lead: University of Trento, Italy Funding Partners: Biogen, Compass Pathways, J&J, MSD Project Launch: 1st February 2022 Project Duration: 36 months Background NEGR1 is one of the most significant risk genes for the development of major depressive disorder, pointing to brain expression upregulation as the mechanism underlying it’s genetic association. Project Plan The researchers will […]
Project 1: Investigating KALRN as a novel target for the treatment of schizophrenia
Lead Institution: University of Oxford Partner Institution: Earlham Institute Funding Partners: Boehringer Ingelheim & Biogen Project Launch: 1st December 2020 Project Duration: 18 months Background KALRN is thought to play an important role in the regulation of neuronal communication, which is known to be altered in the brains of people with schizophrenia. Restoring this communication […]
